RxDoctor Payments Data

Christine Krisch, NP

Adult Health · New York, NYNPI 1487305967

Payments from drug & device makers

$1,471in general payments, 2019–2025

Across 49 payments — averaging $30.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$781
  • E.r. Squibb & Sons, L.L.C.$245
  • Abiomed$148
  • Actelion Pharmaceuticals US, Inc.$70
  • Scpharmaceuticals Inc.$55
  • AstraZeneca$47
  • plus $124 from 5 others

What the payments were for

  • Food & beverage$1,40195%
  • Education$705%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,471 in reported general payments places this provider in the 75th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$1,240
Medicare patients
18
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis40$1,059,183
OpsumitMacitentan41$536,308
UptraviSelexipag19$434,435
AdempasRiociguat29$421,982
EntrestoSacubitril/Valsartan282$359,485
FarxigaDapagliflozin Propanediol258$298,635
Ambrisentan68$277,168
EliquisApixaban175$191,009
AdcircaTadalafil20$119,497
JardianceEmpagliflozin89$92,793
Tadalafil52$46,656
XareltoRivaroxaban22$21,490
Eplerenone190$15,861
VerquvoVericiguat13$12,717
Sildenafil Citrate43$11,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$70$970,74460 claims
AstraZenecaFarxiga$47$298,635258 claims
United Therapeutics CorporationAdcirca$31$119,49720 claims
Boehringer IngelheimJardiance$28$92,79389 claims
MerckVerquvo$23$12,71713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,828 adult health providers in New York.

Other adult health in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →